Su Qiang, Li Tian, Liu Guo-Wei, Zhang Yan-Li, Guo Jun-Hong, Wang Zhao-Jun, Wu Mei-Na, Qi Jin-Shun
Key Laboratory of Cellular Physiology, Ministry of Education; Department of Physiology, Shanxi Medical University; Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
Key Laboratory of Cellular Physiology, Ministry of Education; Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi Province, China.
Neural Regen Res. 2023 Apr;18(4):727-733. doi: 10.4103/1673-5374.353479.
Agomelatine is a selective agonist of melatonin receptor 1A/melatonin receptor 1B (MT/MT) and antagonist of 5-hydroxytryptamine 2C receptors. It is used clinically to treat major depressive episodes in adults. The pro-chronobiological activity of agomelatine reconstructs sleep-wake rhythms and normalizes circadian disturbances via its agonistic effect of melatonin receptor 1A/melatonin receptor 1B, which work simultaneously to counteract depression and anxiety disorder. Moreover, by antagonizing neocortical postsynaptic 5-hydroxytryptamine 2C receptors, agomelatine enhances the release of dopamine and noradrenaline in the prefrontal cortex, increases the activity of dopamine and noradrenaline, and thereby reduces depression and anxiety disorder. The combination of these two effects means that agomelatine exhibits a unique pharmacological role in the treatment of depression, anxiety, and disturbance of the circadian rhythm. Emotion and sleep are closely related to memory and cognitive function. Memory disorder is defined as any forms of memory abnormality, which is typically evident in a broad range of neurodegenerative diseases, including Alzheimer's disease. Memory impairment and cognitive impairment are common symptoms of neurodegenerative and psychiatric diseases. Therefore, whether agomelatine can improve memory and cognitive behaviors if used for alleviating depression and circadian-rhythm sleep disorders has become a research "hotspot". This review presents the latest findings on the effects of agomelatine in the treatment of psychologic and circadian-rhythm sleep disorders in clinical trials and animal experiments. Our review evaluates recent studies on treatment of memory impairment and cognitive impairment in neurodegenerative and psychiatric diseases.
阿戈美拉汀是褪黑素受体1A/褪黑素受体1B（MT1/MT2）的选择性激动剂和5-羟色胺2C受体的拮抗剂。它在临床上用于治疗成人的重度抑郁发作。阿戈美拉汀的促生物钟活性通过其对褪黑素受体1A/褪黑素受体1B的激动作用来重建睡眠-觉醒节律并使昼夜节律紊乱正常化，这两种受体协同作用以对抗抑郁和焦虑症。此外，通过拮抗新皮质突触后5-羟色胺2C受体，阿戈美拉汀增强前额叶皮质中多巴胺和去甲肾上腺素的释放，增加多巴胺和去甲肾上腺素的活性，从而减轻抑郁和焦虑症。这两种作用的结合意味着阿戈美拉汀在治疗抑郁、焦虑和昼夜节律紊乱方面具有独特的药理作用。情绪和睡眠与记忆及认知功能密切相关。记忆障碍被定义为任何形式的记忆异常，这在包括阿尔茨海默病在内的广泛神经退行性疾病中通常很明显。记忆损害和认知损害是神经退行性疾病和精神疾病的常见症状。因此，阿戈美拉汀用于缓解抑郁和昼夜节律性睡眠障碍时是否能改善记忆和认知行为已成为一个研究“热点”。本综述介绍了阿戈美拉汀在临床试验和动物实验中治疗心理和昼夜节律性睡眠障碍效果的最新研究结果。我们的综述评估了近期关于神经退行性疾病和精神疾病中记忆损害和认知损害治疗的研究。
